Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

Propensity score-matched analysis

KAMIR Investigators

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Despite common use of second-generation drug-eluting stents in treating patients with coronary artery disease, there is lack of data comparing these stents exclusively in patients with acute myocardial infarction (AMI), especially with metabolic syndrome (MetS), which is highly prevalent in AMI and potential to worsen clinical outcomes. The aim of this study was to compare clinical outcomes of everolimus-eluting stent (EES) and Resolute-zotarolimus-eluting stent (R-ZES) in AMI patients with MetS, in terms of stent-related and patient-related outcomes. Methods A total of 3942 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were grouped according to the presence of MetS and stent type: EES (N = 1582) and R-ZES (N = 255) in MetS (1837). Target lesion failure (TLF) and patient-oriented composite events (POCE) at 1 year were evaluated. Results In MetS patients, TLF (3.7% vs. 2.7%, p = 0.592) and POCE (7.9% vs. 6.7%, p = 0.764) were similar between EES and R-ZES. Also in Non-MetS patients, TLF (3.9% vs. 3.1%, p = 0.307) and POCE (6.4% vs. 7.3%, p = 0.866) were similar between 2 groups. TLF was similar between MetS and Non-MetS patients (3.6% vs. 3.8%), while POCEs (7.7% vs. 6.6%) were higher in MetS. Propensity-score matching analysis showed similar results between stent groups in MetS and Non-MetS. In multivariate analysis, left ventricular ejection fraction and symptom-to-door time were independent predictors of TLF and POCE in MetS patients with AMI. Conclusions In MetS patients with AMI, EES and R-ZES showed excellent performance and safety. However, patient-oriented composite events were relatively high, suggesting more efforts to improve them.

Original languageEnglish
Pages (from-to)53-62
Number of pages10
JournalInternational Journal of Cardiology
Volume199
DOIs
Publication statusPublished - 2015 Sep 15

Fingerprint

Propensity Score
Stents
Myocardial Infarction
zotarolimus
Everolimus
Drug-Eluting Stents
Korea
Stroke Volume

Keywords

  • Drug-coated stents
  • Metabolic cardiovascular syndrome
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{9f4f348b7bff4bbb8431b8fc50c77ae2,
title = "Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: Propensity score-matched analysis",
abstract = "Background Despite common use of second-generation drug-eluting stents in treating patients with coronary artery disease, there is lack of data comparing these stents exclusively in patients with acute myocardial infarction (AMI), especially with metabolic syndrome (MetS), which is highly prevalent in AMI and potential to worsen clinical outcomes. The aim of this study was to compare clinical outcomes of everolimus-eluting stent (EES) and Resolute-zotarolimus-eluting stent (R-ZES) in AMI patients with MetS, in terms of stent-related and patient-related outcomes. Methods A total of 3942 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were grouped according to the presence of MetS and stent type: EES (N = 1582) and R-ZES (N = 255) in MetS (1837). Target lesion failure (TLF) and patient-oriented composite events (POCE) at 1 year were evaluated. Results In MetS patients, TLF (3.7{\%} vs. 2.7{\%}, p = 0.592) and POCE (7.9{\%} vs. 6.7{\%}, p = 0.764) were similar between EES and R-ZES. Also in Non-MetS patients, TLF (3.9{\%} vs. 3.1{\%}, p = 0.307) and POCE (6.4{\%} vs. 7.3{\%}, p = 0.866) were similar between 2 groups. TLF was similar between MetS and Non-MetS patients (3.6{\%} vs. 3.8{\%}), while POCEs (7.7{\%} vs. 6.6{\%}) were higher in MetS. Propensity-score matching analysis showed similar results between stent groups in MetS and Non-MetS. In multivariate analysis, left ventricular ejection fraction and symptom-to-door time were independent predictors of TLF and POCE in MetS patients with AMI. Conclusions In MetS patients with AMI, EES and R-ZES showed excellent performance and safety. However, patient-oriented composite events were relatively high, suggesting more efforts to improve them.",
keywords = "Drug-coated stents, Metabolic cardiovascular syndrome, Myocardial infarction",
author = "{KAMIR Investigators} and Ji, {Mi Seon} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Kim, {Sang Hyung} and Kim, {Young Jo} and Chae, {Shung Chull} and Hong, {Taek Jong} and Seong, {In Whan} and Chae, {Jei Keon} and Kim, {Chong Jin} and Cho, {Myeong Chan} and Seung-Woon Rha and Bae, {Jang Ho} and Seung, {Ki Bae} and Park, {Seung Jung} and Hur, {Seung Ho} and Kim, {Doo Il} and Chae, {In Ho} and Yoon, {Jung Han} and Koo, {Bon Kwon} and Kim, {Byung Ok} and Lee, {Myoung Yong} and KeeSik Kim and Hwang, {Jin Yong} and NaeHee Lee and Jeong, {Kyoung Tae} and Tahk, {Seung Jea} and Ahn, {Tae Hoon} and Kim, {Moo Hyun} and Yang, {Ju Young} and Rhim, {Chong Yun} and Gwon, {Hyeon Cheol} and Park, {Seong Wook} and Koh, {Young Youp} and Joo, {Seung Jae} and Kim, {Soo Joong} and Jin, {Dong Kyu} and Cho, {Jin Man} and Jang, {Yang Soo} and Cho, {Jeong Gwan}",
year = "2015",
month = "9",
day = "15",
doi = "10.1016/j.ijcard.2015.07.010",
language = "English",
volume = "199",
pages = "53--62",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction

T2 - Propensity score-matched analysis

AU - KAMIR Investigators

AU - Ji, Mi Seon

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Kim, Sang Hyung

AU - Kim, Young Jo

AU - Chae, Shung Chull

AU - Hong, Taek Jong

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Kim, Chong Jin

AU - Cho, Myeong Chan

AU - Rha, Seung-Woon

AU - Bae, Jang Ho

AU - Seung, Ki Bae

AU - Park, Seung Jung

AU - Hur, Seung Ho

AU - Kim, Doo Il

AU - Chae, In Ho

AU - Yoon, Jung Han

AU - Koo, Bon Kwon

AU - Kim, Byung Ok

AU - Lee, Myoung Yong

AU - Kim, KeeSik

AU - Hwang, Jin Yong

AU - Lee, NaeHee

AU - Jeong, Kyoung Tae

AU - Tahk, Seung Jea

AU - Ahn, Tae Hoon

AU - Kim, Moo Hyun

AU - Yang, Ju Young

AU - Rhim, Chong Yun

AU - Gwon, Hyeon Cheol

AU - Park, Seong Wook

AU - Koh, Young Youp

AU - Joo, Seung Jae

AU - Kim, Soo Joong

AU - Jin, Dong Kyu

AU - Cho, Jin Man

AU - Jang, Yang Soo

AU - Cho, Jeong Gwan

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Background Despite common use of second-generation drug-eluting stents in treating patients with coronary artery disease, there is lack of data comparing these stents exclusively in patients with acute myocardial infarction (AMI), especially with metabolic syndrome (MetS), which is highly prevalent in AMI and potential to worsen clinical outcomes. The aim of this study was to compare clinical outcomes of everolimus-eluting stent (EES) and Resolute-zotarolimus-eluting stent (R-ZES) in AMI patients with MetS, in terms of stent-related and patient-related outcomes. Methods A total of 3942 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were grouped according to the presence of MetS and stent type: EES (N = 1582) and R-ZES (N = 255) in MetS (1837). Target lesion failure (TLF) and patient-oriented composite events (POCE) at 1 year were evaluated. Results In MetS patients, TLF (3.7% vs. 2.7%, p = 0.592) and POCE (7.9% vs. 6.7%, p = 0.764) were similar between EES and R-ZES. Also in Non-MetS patients, TLF (3.9% vs. 3.1%, p = 0.307) and POCE (6.4% vs. 7.3%, p = 0.866) were similar between 2 groups. TLF was similar between MetS and Non-MetS patients (3.6% vs. 3.8%), while POCEs (7.7% vs. 6.6%) were higher in MetS. Propensity-score matching analysis showed similar results between stent groups in MetS and Non-MetS. In multivariate analysis, left ventricular ejection fraction and symptom-to-door time were independent predictors of TLF and POCE in MetS patients with AMI. Conclusions In MetS patients with AMI, EES and R-ZES showed excellent performance and safety. However, patient-oriented composite events were relatively high, suggesting more efforts to improve them.

AB - Background Despite common use of second-generation drug-eluting stents in treating patients with coronary artery disease, there is lack of data comparing these stents exclusively in patients with acute myocardial infarction (AMI), especially with metabolic syndrome (MetS), which is highly prevalent in AMI and potential to worsen clinical outcomes. The aim of this study was to compare clinical outcomes of everolimus-eluting stent (EES) and Resolute-zotarolimus-eluting stent (R-ZES) in AMI patients with MetS, in terms of stent-related and patient-related outcomes. Methods A total of 3942 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were grouped according to the presence of MetS and stent type: EES (N = 1582) and R-ZES (N = 255) in MetS (1837). Target lesion failure (TLF) and patient-oriented composite events (POCE) at 1 year were evaluated. Results In MetS patients, TLF (3.7% vs. 2.7%, p = 0.592) and POCE (7.9% vs. 6.7%, p = 0.764) were similar between EES and R-ZES. Also in Non-MetS patients, TLF (3.9% vs. 3.1%, p = 0.307) and POCE (6.4% vs. 7.3%, p = 0.866) were similar between 2 groups. TLF was similar between MetS and Non-MetS patients (3.6% vs. 3.8%), while POCEs (7.7% vs. 6.6%) were higher in MetS. Propensity-score matching analysis showed similar results between stent groups in MetS and Non-MetS. In multivariate analysis, left ventricular ejection fraction and symptom-to-door time were independent predictors of TLF and POCE in MetS patients with AMI. Conclusions In MetS patients with AMI, EES and R-ZES showed excellent performance and safety. However, patient-oriented composite events were relatively high, suggesting more efforts to improve them.

KW - Drug-coated stents

KW - Metabolic cardiovascular syndrome

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84941636294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941636294&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.07.010

DO - 10.1016/j.ijcard.2015.07.010

M3 - Article

VL - 199

SP - 53

EP - 62

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -